Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access

Set Alert for Market Access

Novartis Has Blockbuster Targets For Cosentyx In New Autoimmune Indications

Next up for Cosentyx is psoriatic arthritis and ankylosing spondylitis. Novartis presented impressive long-term efficacy data at ACR in PsA and AS. Incoming CEO and Chief Medical Officer Vas Narasimhan said the company sees a blockbuster opportunity and is exploring the anti-TNF naïve market in AS.

Clinical Trials Immune Disorders Research and Development Strategies
Advertisement

Market Access

Set Alert for Market Access

Latest From Market Access

Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine

Novartis and Amgen are trying to build a compelling case for the value of their CGRP antagonist erenumab. Novartis said one strategy under consideration is to underwrite the cost of the drug for patients who don't respond.

Reimbursement Market Access

ACR Notebook: Lilly's Baricitinib Differentiates On Pain, Ironwood's Duzallo Progress, Corbus Nears Phase III

The ACR/ARHP Annual Meeting in San Diego offered new details from studies of new and existing therapies across a range of rheumatic diseases, from rheumatoid arthritis to rare diseases. Scrip shares notes here from interviews with Lilly, Ironwood, Corbus and Samumed.

Business Strategies Clinical Trials

Payer Pushback Underpins Mallinckrodt's Disappointing Q3 Results

Mallinckrodt's high-priced H.P Acthar Gel was under pressure in the third quarter, which management attributed to payer complexities. The issue is broader than just Acthar, firm says.

Sales & Earnings Reimbursement

Interview: Alnylam President On Patisiran Lift-Off Plans

Barry Greene, president of Alnylam, tells Scrip that the company is happy to consider risk-sharing with payers, as the firm is confident about the 'extreme value' that its RNAi therapeutic for hATTR amyloidosis will offer, if approved.

Companies Commercial

Set, Ready, Walk: Gilead Unveils Sovaldi Strategy In China

Rapid regulatory changes in China are expected to trigger a flurry of new drug launch activities. As Q3 earnings season plays out, Gilead COO Kevin Young talks about doing ‘the right thing’ while rolling out products like the high-priced Sovaldi in China's private-pay market.

Asia Pacific Commercial

UK To Offer Firms More Flexible Commercial Deals On ‘Transformative’ Drugs, Earlier Access To Market

Companies seeking to have their innovative drugs made available on the NHS in England could benefit from government plans to offer “transformative” new products access to the market up to four years earlier than under the standard assessment route.

Market Access Innovation
See All
UsernamePublicRestriction

Register